Upside Purchased on Matrixx Initiatives (MTXX)

Shares of Matrixx Initiatives (NASDAQ: MTXX) are higher on the session by 1.36%, currently trading at $5.22. The stock has been moving largely sideways for the past six months, but has managed to regain the 50-day moving average as of late.

Options traders are echoing that upside movement by buying calls today. Though action has been primarily in smaller lots, call volume is now running at 19.78x the daily average with 86% of all calls traded being purchases on the offer.

Traders are buying the $5.00 and $7.50 call in multiple months.

Matrixx Initiatives, Inc. develops, produces, markets and sells over-the-counter healthcare products with an emphasis on those that utilize delivery systems. Through its subsidiary, Zicam, LLC, the company markets and sells products under the Zicam brand. The Company's product offerings include Cold Remedy Nasal; Cold Remedy Oral; Allergy/Sinus; Cough and Multi-Symptom, Antacid and other cough/cold. The company has sales in one business segment, over-the-counter pharmaceuticals and dietary supplements.

For more great research like this, as well as how to play it through options…please visit Benzinga’s Options & Volatility Edge and Benzinga’s Cash Generator.